Tabula Rasa HealthCare stock (US89400K1088): focus shifts after sale of core business to ExactCare

Tabula Rasa HealthCare has sold its main CareVention HealthCare business to ExactCare Pharmacy, reshaping the company and its stock profile. What this strategic move could mean for investors and the future structure of the group.

Tabula Rasa HealthCare stock has entered a transition phase after the company completed the sale of its CareVention HealthCare division, including the MedWise technology, to ExactCare Pharmacy, a subsidiary of Nautic Partners, according to a company press release dated 02/09/2024 Tabula Rasa HealthCare as of 02/09/2024. The transaction significantly reshapes the group’s business mix and leaves investors watching how the remaining operations and capital structure will evolve, especially given the company’s historical focus on medication risk management.

As of: 21.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Tabula Rasa HealthCare
• Sector/industry: Healthcare technology and pharmacy services
• Headquarters/country: Moorestown, New Jersey, USA
• Core markets: Medication safety solutions and pharmacy services for US healthcare providers
• Key revenue drivers: Clinical pharmacy services, software-enabled medication risk management, contracts with US healthcare organizations
• Home exchange/listing venue: Nasdaq (ticker: TRHC)
• Trading currency: USD

Tabula Rasa HealthCare: core business model

Tabula Rasa HealthCare has historically focused on reducing medication-related risk for complex patient populations in the United States. The company’s core idea has been to use clinical pharmacy expertise and proprietary decision-support tools to identify potentially harmful drug interactions, particularly for older patients taking multiple medications. This niche sits at the intersection of healthcare IT, data analytics and pharmacy services, targeting payers and providers that need to manage costs and patient safety.

Over the years, the group organized its activities mainly through the CareVention HealthCare and MedWise HealthCare segments, serving programs like Programs of All-Inclusive Care for the Elderly (PACE) alongside other risk-bearing healthcare organizations. Its technologies aimed to quantify cumulative drug burden and predict adverse outcomes, helping clinicians adjust medication regimens. This model generated revenue from long-term contracts, software and analytics fees, and clinical service arrangements tied to patient populations rather than single prescriptions.

Following the sale of CareVention to ExactCare Pharmacy announced in February 2024, the structure of Tabula Rasa HealthCare changed materially. The transaction carved out a substantial portion of the company’s historical revenue base and transferred operational control of core assets, including MedWise, to a strategic buyer in the pharmacy services space, according to the transaction announcement Tabula Rasa HealthCare as of 02/09/2024. The remaining entity retains responsibilities around corporate-level obligations and any continuing activities that were not part of the sale, positioning the stock more as a special situation than a traditional growth story for the time being.

Main revenue and product drivers for Tabula Rasa HealthCare

Before the divestiture, Tabula Rasa HealthCare’s main revenue drivers were software-enabled clinical services embedded in client workflows. The company monetized its MedWise technology through subscription licenses to healthcare organizations and by integrating the algorithms into comprehensive pharmacy service packages. Revenue was closely tied to the number of enrolled patients and the depth of services, making scaling with new clients and patient cohorts a key growth lever. Long-term contracts with PACE and similar programs offered recurring revenue and visibility, while new client wins supported incremental growth.

The sale to ExactCare Pharmacy reallocated much of this engine. As of the closing announcement, CareVention’s pharmacy and technology operations, including MedWise, moved under ExactCare’s umbrella, consolidating clinical pharmacy and analytics capabilities in one platform. For Tabula Rasa HealthCare shareholders, the value proposition therefore shifted from ongoing operational growth to the financial outcome of the transaction and the way proceeds are used to manage debt or future obligations. Details from earlier filings indicated that the company had faced leverage and liquidity considerations, making balance sheet repositioning an important theme for investors following the deal.

In the US healthcare context, medication-related harm and polypharmacy remain major cost drivers, and solutions that help physicians rationalize complex regimens have attracted attention from payers and policymakers alike. Even after the asset sale, Tabula Rasa HealthCare’s legacy in this field provides context for the stock’s past volatility and investor interest. The company’s earlier revenue mix, centered on software, clinical services and risk-sharing arrangements, reflected broader trends in value-based care and the shift from fee-for-service to outcome-linked payments in the US market.

Industry trends and competitive position

The healthcare technology and medication safety sector in the US has been shaped by demographic dynamics and regulatory incentives. An aging population and the high prevalence of chronic diseases drive polypharmacy, which in turn increases the risk of adverse drug events. Payers and providers therefore look for tools to manage medication complexity while keeping costs under control. This has created a market for clinical decision support systems, predictive analytics and integrated pharmacy services that can identify high-risk patients and guide interventions.

Tabula Rasa HealthCare built its reputation in this environment by emphasizing quantitative modeling of medication risk rather than simply flagging interactions. The MedWise platform was marketed as a way to move beyond traditional drug-drug interaction checks, using algorithms to evaluate the cumulative impact of medication regimens on individual patients. Competitors in this arena include large electronic health record vendors, pharmacy benefit managers and specialized analytics firms, many of which integrate medication alerts into broader population health platforms. The niche is therefore competitive, but the addressable market is large given the scale of US healthcare spending.

With the CareVention assets and MedWise now under ExactCare Pharmacy, the competitive dynamics for those solutions will be driven by the new owner’s strategy and investment capacity. For investors tracking Tabula Rasa HealthCare stock, this means that the company’s former competitive position within clinical pharmacy technology is no longer a direct driver of operational results. Instead, the stock reflects residual interests, corporate-level considerations and any remaining activities not included in the transaction. The wider industry trends remain relevant, however, as they help explain why the divested assets attracted a specialized acquirer and how value may be realized in the broader ecosystem.

Why Tabula Rasa HealthCare matters for US investors

From a US investor perspective, Tabula Rasa HealthCare has served as a case study in the opportunities and risks of niche healthcare technology models. The company operated at the intersection of software, services and regulated healthcare delivery, a space where business performance can be highly sensitive to reimbursement, client adoption patterns and operational execution. Its Nasdaq listing and focus on US healthcare organizations made it a small-cap name tied closely to domestic policy debates and value-based care initiatives.

The sale of CareVention to ExactCare Pharmacy materially alters the stock’s profile. Investors who previously viewed Tabula Rasa HealthCare as a growth-oriented healthcare IT and services provider must now evaluate it through the lens of corporate restructuring and the outcome of strategic transactions. For US market participants, this highlights the importance of balance sheet strength, capital allocation decisions and the timing of strategic reviews in specialized healthcare companies. It also underscores how shifts in strategy can change the risk-return profile of a stock, even when the underlying healthcare need—reducing medication risk in complex patients—remains pressing.

US investors who follow the wider healthcare technology space may also see the Tabula Rasa HealthCare story as indicative of consolidation trends. As reimbursement pressures and technology costs rise, smaller innovators sometimes choose or are forced to combine with larger platforms that can distribute their solutions at scale. The ExactCare transaction points to the value that established pharmacy service providers see in advanced medication risk analytics, while leaving public market shareholders to assess how that value is captured in the listed entity over time.

Conclusion

Tabula Rasa HealthCare has undergone a fundamental transformation with the sale of its CareVention business and MedWise technology to ExactCare Pharmacy, shifting the stock’s narrative from operational growth to strategic repositioning. The company’s historical role in medication risk management and value-based care provides important context, but the key questions for shareholders now center on how transaction proceeds affect the balance sheet, what residual activities remain, and how management communicates the next steps. For investors in the US and abroad, the case illustrates both the potential of specialized healthcare technology and the structural challenges such companies can face when market conditions, leverage and strategic options converge.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.